Search
2025
2024
2023
-
Feb 25, 2025
YolTech Therapeutics Announces Positive Clinical Data for YOLT-203, an In Vivo Gene Editing Therapy for Primary Hyperoxaluria Type 1 (PH1)Read More
-
Dec 21, 2024
YolTech Completes Dose Escalation in YOLT-201 Phase I TrialRead More
-
Oct 31, 2024
YolTech Awarded Patent for Novel Lipid Nanoparticle Technology, Strengthening In-House Delivery CapabilitiesRead More
-
Sep 23, 2024
YolTech Receives U.S. FDA ODD for YOLT-203 in Treating PH1Read More
-
Sep 04, 2024
YolTech Receives U.S. FDA RPDD for YOLT-203 in Treating PH1Read More
